What’s trending today? Are you looking at penny stocks? Even if you aren’t, you’ll want to know why specific stocks are making moves, whether good or bad. Here are a handful of topics to consider during your thought process.
More than anything, news or a press release will be the major standout. Filings can be more of a backup to be looking at, but can still be a key trigger. Heck, even rumors that crop up on the interwebs can be enough to get a penny stock moving in a vertical direction. Ciphering through all of these can help you to potentially be the first in line, or just another gripping onto the idea of the Fear Of Missing Out (FOMO).
As soon as you can lock into these basic ideas and find the best info regarding penny stocks, you can then start putting a watch-list together. As we’ve seen in recent weeks, there have been a number of major evens, some with headlines as big as a China trade war, Covid-19, SpaceX, and the protests/rioting.
Knowing how events like these can directly effect penny stocks can give you the freedom to maneuver through a murky, volatile market environment. Taking this into consideration, lets look at a handful of penny stocks that could be on the move next.
Your No. 1 Top Penny Stock To Watch In The Short-term: FSD Pharma Inc.
FSD Pharma Inc. (Nasdaq: HUGE), through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain.
FSD Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
“FDA’s permission to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-201 is a paradigm shift for FSD Pharma and is the result of outstanding work conducted by Dr. Edward Brennan , President FSD BioSciences, and his team,” said Raza Bokhari , MD, Executive Co-Chairman & CEO. “We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultramicronized PEA for patients suffering from symptoms of COVID-19, based on the drug’s mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines. Numerous studies over the past 40 years also validate the efficacy and safety of ultramicronized PEA in the treatment and prophylactic effects in respiratory infections. These studies also pointed out that the ease of application of PEA offers the possibility to have a quick therapeutic answer ready in case of a flu epidemic.”
Your No. 2 Top Penny Stock To Watch In The Short-term: OpGen, Inc.
OpGen, Inc. (Nasdaq: OPGN), a precision medicine company, develops and sells molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MRDOs).
The company’s products include Acuitas AMR Gene Panel, an in vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are diagnostic tests for the identification of various infectious pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment.
OpGen, Inc. announced that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is entering into its second year expansion phase. Having successfully achieved all of the milestones of the first year pilot phase for the development of an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance, OpGen will continue to work together with DOH’s Wadsworth Center, participating healthcare systems, and collaborators such as Infectious Disease Connect, Inc. (IDC), which recently combined with ILÚM Health Solutions, to expand the reach of the platform, increase the volume of testing, and enhance data collection.
“We are excited and grateful that despite the continued threat of the COVID-19 pandemic which has hit New York State harder than any other place in the world, the Department of Health of New York State and the Wadsworth Center continue to work with us and have expanded their partnership for a second year, adding up to 3,500 AMR Gene Panel tests to be run,” commented Oliver Schacht, CEO of OpGen. “The quick spread of antimicrobial resistant superbugs across our healthcare systems is lurking below the current medical crisis. We anticipate that with our innovative diagnostic solutions we will be able to proactively identify such pathogens leading to early intervention and lifesaving treatment. A further project expansion of this nature may include the exploration of ways to achieve SARS-CoV-2 tracking.”
Your No. 3 Top Penny Stock To Watch In The Short-term: Secoo Holding Limited
Secoo Holding Limited (Nasdaq: SECO), through its subsidiaries, operates an integrated online and offline shopping platform in Mainland China, Hong Kong, and other countries. The company provides upscale brand products and services, including bags, watches, women’s and men’s wear, footwear, children’s wear, sportswear, cosmetics and skin care products, jewelry, accessories, home goods, fine food and beverage products, arts, and Chinese original products, as well as lifestyle services through its Website, mobile applications, and offline experience centers. It also offers its Website as a marketplace to third party merchants to facilitate their sales of upscale products and services.
Secoo Holding Limited and Qudian, Inc., a leading technology platform empowering the enhancement of online consumer finance experience in China, announced today that Secoo and Qudian have entered into a definitive agreement, pursuant to which Qudian has agreed to purchase a total of up to 10,204,082 newly issued Class A ordinary shares of Secoo for an aggregate purchase price of up to US$100,000,003.60, reflecting a per share purchase price of US$9.80.
Following the completion of all transactions contemplated under the definitive agreement, Qudian will hold approximately 28.9% of Secoo’s issued and outstanding shares.
In addition, Secoo and Qudian will also enter into a business cooperation agreement, which will set forth the key areas for the two companies’ strategic cooperation in the online luxury e-commerce business space.
Mr. Rixue Li, Founder, Chairman and Chief Executive Officer of Secoo, said, “We believe this strategic partnership will enable us to accelerate growth by building upon both companies’ assets, core expertise and competitive advantages. We will utilize the investment proceeds to further strengthen the supply chain and enhance user satisfaction.”